Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is expected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.76) per share and revenue of $14.81 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $34.71 on Wednesday. Kymera Therapeutics has a fifty-two week low of $29.24 and a fifty-two week high of $53.27. The stock has a 50 day moving average price of $39.46 and a two-hundred day moving average price of $43.97. The company has a market capitalization of $2.25 billion, a P/E ratio of -14.83 and a beta of 2.18.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the transaction, the insider now owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.82% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

KYMR has been the subject of a number of recent analyst reports. Stephens restated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Morgan Stanley increased their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Truist Financial reiterated a “buy” rating and issued a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Leerink Partners reissued an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Finally, UBS Group cut their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $55.64.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.